Category: Johnson & JohnsonSyndicate content

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

October 24, 2014 by MassDevice

A federal jury in Texas clears Johnson & Johnson's DePuy Pinnacle hip implant in the 1st bellwether product liability trial over the metal-on-metal device.

Johnson & Johnson's DePuy wins first trial over Pinnacle hips

BREAKING: Jury clears DePuy in 1st Pinnacle bellwether trial

October 23, 2014 by Brad Perriello

A federal jury in Texas reportedly clears Johnson & Johnson's DePuy Pinnacle hip implant in the 1st bellwether product liability trial over the metal-on-metal device.

BREAKING: Jury clears DePuy in 1st Pinnacle bellwether trial

UPDATED Oct. 23, 2014, with comment from DePuy.

Jury deliberations begin in first trial over DePuy's Pinnacle hips

October 22, 2014 by MassDevice

A jury begins deliberations in the 1st trial over DePuy Orthopaedics' Pinnacle metal-on-metal hip implant.

Jury deliberations begin in first trial over DePuy's Pinnacle hips

JNJ/Synthes integration continues to bring hefty charges | The week in medtech M&A

October 22, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

Covidien wins injunction against J&J unit's surgical shears

October 17, 2014 by Brad Perriello

A federal judge bars sales of Johnson & Johnson unit Ethicon Endo-Surgery's Harmonic Ace +7 surgical shears in a patent infringement lawsuit brought by Covidien.

Covidien wins injunction against J&J unit's surgical shears

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.

JNJ continues to pay hefty integration charges on Synthes deal

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

J&J sales top forecast, helped by hepatitis drug

October 14, 2014 by MassDevice

Johnson & Johnson's 2nd-quarter sales top forecasts, prompting the medical product giant to raise its full-year earnings guidance.

J&J sales top forecast, helped by hepatitis drug

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp